Amgen's Immunology Narrative Reshaped by Positive TEZSPIRE Trial Results

The Amgen's immunology narrative has been reshaped by the positive Phase 3 CROSSING trial results for TEZSPIRE, a first-in-class antibody developed in collaboration with AstraZeneca. The trial showed that TEZSPIRE achieved significant improvements in key eosinophilic esophagitis outcomes, demonstrating its potential as a treatment for this disease.

The success of TEZSPIRE in the CROSSING trial has added another use case to Amgen's diversified portfolio and late-stage pipeline. However, investors are still waiting for more data on the cardiovascular and obesity assets, which remain key near-term catalysts for the company. The biggest risk facing Amgen remains pressure on pricing and margins as older products face competition.

Repatha's VESALIUS CV mortality data, which showed a 20% reduction in all-cause mortality and a 25% reduction in major cardiac events in high-risk patients without prior heart attack or stroke, has also caught investors' attention. The read-across risk from Novartis's pelacarsen miss for olpasiran further highlights the focus on outcomes-driven specialty medicines.

Despite these growth drivers, investors should be aware of the mounting risk that drug pricing reforms and value-based care could cap Amgen's long-term profitability. Analysts have different views on the company's future, with some forecasting $41.5 billion in revenue and $10.3 billion in earnings by 2029.

The fair value of Amgen is estimated to be around $371.93, which represents a 15% downside from its current price. Investors are advised to carefully consider the data and build their own conviction before making investment decisions.